Publication | Open Access
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
31
Citations
16
References
2023
Year
US Food and Drug Administration Office of Orphan Products Development and Orphazyme.
| Year | Citations | |
|---|---|---|
Page 1
Page 1